ARTICLE | Finance

Hallway Chatter

Intarcia, Anchor, Xencor provide 3 stories at BIO Investor Forum

October 11, 2010 7:00 AM UTC

Companies were busy rolling out their wish lists at the annual BIO Investor Forum in San Francisco last week. Among them was new Executive Chairman Kurt Graves of Intarcia Therapeutics Inc. (formerly BioMedicines Inc.), who said the biotech needs to secure a partner before it starts Phase III testing of its Duros device for continuous subcutaneous delivery of stabilized exenatide to treat Type II diabetes. The company hopes to start the studies early next year.

The device would be implantable in a procedure in a physician's office once or twice a year, which Graves said provides an edge over once-weekly delivery...